Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
-
Published:2024-01
Issue:1
Volume:9
Page:102202
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Ajani J.,
El Hajbi F.,
Cunningham D.,
Alsina M.,
Thuss-Patience P.ORCID,
Scagliotti G.V.ORCID,
Van den Eynde M.,
Kim S-B.,
Kato K.ORCID,
Shen L.,
Li L.,
Ding N.,
Shi J.ORCID,
Barnes G.,
Van Cutsem E.
Subject
Cancer Research,Oncology